Targeted Oncology2d
Key Advances in Oncology: Top Highlights From ESMO 2024
Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Targeted Oncology15d
Lenvatinib and Pembrolizumab Combo Breaks New Ground in Non–Clear Cell RCC
2 Similarly, the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) resulted in an ORR of 54% and a median PFS of 17.4 months. 3 “In terms of overall survival [OS], we are also seeing a ...
Frontiers25d
A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system
Introduction: Sotorasib and adagrasib have been widely used for the non-small cell lung cancer (NSCLC) patients harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation. It's ...
urologytimes25d
Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management
Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its ...
Frontiers28d
Durable response to pembrolizumab in hepatic metastasis from colonic carcinoma with Lynch syndrome: a case report
Pembrolizumab and other immunotherapies have become central in treating metastatic colon cancer, particularly effective in patients with mismatch repair deficiencies. We report a case involving a man ...